Related references
Note: Only part of the references are listed.Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?
Pierre Blanchard et al.
LANCET ONCOLOGY (2018)
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial
Lin-Quan Tang et al.
LANCET ONCOLOGY (2018)
Comparison of efficacy and toxicity between nedaplatin and cisplatin in treating malignant pleural effusion
Li-Zhe Zhong et al.
ONCOTARGETS AND THERAPY (2018)
Combined study on clastogenic, aneugenic and apoptotic properties of doxorubicin in human cells in vitro
Vasiliki Chondrou et al.
JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI (2018)
Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis
Fei Zhang et al.
DISEASES OF THE ESOPHAGUS (2017)
Liposomal Formulations in Clinical Use: An Updated Review
Upendra Bulbake et al.
PHARMACEUTICS (2017)
Platinum-based drugs: past, present and future
Shahana Dilruba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer
Yijun Tian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition
Chong Zhang et al.
ONCOLOGY LETTERS (2016)
Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells
Huan Wang et al.
ONCOLOGY LETTERS (2016)
Role of PTEN in Oxidative Stress and DNA Damage in the Liver of Whole-Body Pten Haplodeficient Mice
Ezgi Eyluel Bankoglu et al.
PLOS ONE (2016)
Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis
Yun Liu et al.
SCIENTIFIC REPORTS (2015)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
CCN2 Enhances Resistance to Cisplatin-Mediating Cell Apoptosis in Human Osteosarcoma
Hsiao-Chi Tsai et al.
PLOS ONE (2014)
Platinum Compounds: A Hope for Future Cancer Chemotherapy
Imran Ali et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Application of liposomal technologies for delivery of platinum analogs in oncology
Demin Liu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Laboratory Intercomparison on the γ-H2AX Foci Assay
K. Rothkamm et al.
RADIATION RESEARCH (2013)
Intervention Effects of Nedaplatin and Cisplatin on Proliferation and Apoptosis of Human Tumour Cells in Vitro
Xiang-Yu Su et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Protective effect of bixin on cisplatin-induced genotoxicity in PC12 cells
Graciela Cristina dos Santos et al.
FOOD AND CHEMICAL TOXICOLOGY (2012)
53BP1-mediated DNA double strand break repair: Insert bad pun here
Angela T. Noon et al.
DNA REPAIR (2011)
γH2AX foci analysis for monitoring DNA double-strand break repair Strengths, limitations and optimization
Markus Loebrich et al.
CELL CYCLE (2010)
Size of thermosensitive liposomes influences content release
Martin Hossann et al.
JOURNAL OF CONTROLLED RELEASE (2010)
53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination
Anne Bothmer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Emergence of Micronuclei and Their Effects on the Fate of Cells under Replication Stress
Koh-ichi Utani et al.
PLOS ONE (2010)
A minority of foci or pan-nuclear apoptotic staining of γH2AX in the S phase after UV damage contain DNA double-strand breaks
Sebastien de Feraudy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
53BP1: function and mechanisms of focal recruitment
Jennifer E. FitzGerald et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Kinetics of H2AX Phosphorylation After Exposure to Cisplatin
Peggy L. Olive et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2009)
Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy
P. H. Clingen et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Comparison of different methods for an accurate assessment of cytotoxicity in the in vitro micronucleus test I.: Theoretical aspects
E. Lorge et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks
Thomas M. Marti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
γ-H2AX formation in response to interstrand crosslinks requires XPF in human cells
Seiki Mogi et al.
DNA REPAIR (2006)
Protein interactions with platinum-DNA adducts: from structure to function
SG Chaney et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2004)
Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors
CH Bassing et al.
CELL (2003)
H2AX haploinsufficiency modifies genomic stability and tumor susceptibility
A Celeste et al.
CELL (2003)
Genomic instability in mice lacking histone H2AX
A Celeste et al.
SCIENCE (2002)
Share Paper
